These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17884683)

  • 1. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.
    Surmeier DJ
    Lancet Neurol; 2007 Oct; 6(10):933-8. PubMed ID: 17884683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease.
    Chan CS; Gertler TS; Surmeier DJ
    Mov Disord; 2010; 25 Suppl 1():S63-70. PubMed ID: 20187241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Affinity of Isradipine for L-Type Ca
    Ortner NJ; Bock G; Dougalis A; Kharitonova M; Duda J; Hess S; Tuluc P; Pomberger T; Stefanova N; Pitterl F; Ciossek T; Oberacher H; Draheim HJ; Kloppenburg P; Liss B; Striessnig J
    J Neurosci; 2017 Jul; 37(28):6761-6777. PubMed ID: 28592699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What causes the death of dopaminergic neurons in Parkinson's disease?
    Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA
    Prog Brain Res; 2010; 183():59-77. PubMed ID: 20696315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.
    Surmeier DJ; Halliday GM; Simuni T
    Exp Neurol; 2017 Dec; 298(Pt B):202-209. PubMed ID: 28780195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
    Chan CS; Guzman JN; Ilijic E; Mercer JN; Rick C; Tkatch T; Meredith GE; Surmeier DJ
    Nature; 2007 Jun; 447(7148):1081-6. PubMed ID: 17558391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.
    Brimblecombe KR; Connor-Robson N; Bataille CJR; Roberts BM; Gracie C; O'Connor B; Te Water Naude R; Karthik G; Russell AJ; Wade-Martins R; Cragg SJ
    Eur J Neurosci; 2024 Mar; 59(6):1242-1259. PubMed ID: 37941514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The origins of oxidant stress in Parkinson's disease and therapeutic strategies.
    Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA
    Antioxid Redox Signal; 2011 Apr; 14(7):1289-301. PubMed ID: 20712409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium homeostasis, selective vulnerability and Parkinson's disease.
    Chan CS; Gertler TS; Surmeier DJ
    Trends Neurosci; 2009 May; 32(5):249-56. PubMed ID: 19307031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.
    Surmeier DJ; Guzman JN; Sanchez-Padilla J
    Cell Calcium; 2010 Feb; 47(2):175-82. PubMed ID: 20053445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detrimental deletions: mitochondria, aging and Parkinson's disease.
    Biskup S; Moore DJ
    Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium and Parkinson's disease.
    Surmeier DJ; Schumacker PT; Guzman JD; Ilijic E; Yang B; Zampese E
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1013-1019. PubMed ID: 27590583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.